Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Relapsed Neuroblastoma: early-phase trial registry
7 of 9 indexed Relapsed Neuroblastoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,916 of 28,707 conditions by registered trial count.
9 US clinical trials · 7 currently recruiting · #1,916 of 28,707 conditions by registered trial count
Relapsed Neuroblastoma: 9 US clinical trials tracked, 7 recruiting.
Relapsed Neuroblastoma is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most active sponsor is Stephan Grupp MD PhD, running 2 of these trials.
Enrollment posture brief
Registry condition relapsed-neuroblastoma
OPEN 7 | RECR 78% | LATE 0 | EARLY 8 | RANK #1916 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Advanced Colorectal Carcinoma (78% recruiting · 9 trials)
Relapsed Neuroblastoma lists 7 open slots (78% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Relapsed Neuroblastoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Relapsed Neuroblastoma is recruiting above its size-band peers.
7 of 9 indexed trials (77.8%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Relapsed Neuroblastoma research.
Stephan Grupp MD PhD accounts for 2 of 9 trials (22.2%). 8 distinct sponsors appear on at least one study for this condition label.
-
Most Relapsed Neuroblastoma trials plan to enrol fewer than 100 people.
Median target enrolment is 42 among the 9 trials that report a genuine target (sentinel values excluded). 9 of those (100%) plan for fewer than 100 participants.
-
Relapsed Neuroblastoma research is mostly interventional.
8 interventional and 1 observational studies make up this index (88.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
9 total, page 1 of 1
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Theodore Laetsch
NCT06721689
GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma
Stephan Grupp MD PhD
NCT05650749
Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma
Roberto Chiarle
NCT06803875
PHOX2B PC-CAR T Cells for Relapsed Neuroblastoma
Stephan Grupp MD PhD
NCT07007117
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Nationwide Children's Hospital
NCT04211675
Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma
Emory University
NCT05400603
Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma
Steven DuBois, MD
NCT07027748
Parental Decision-Making for Children With Relapsed Neuroblastoma
Dana-Farber Cancer Institute
NCT02282735
C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)
Baylor College of Medicine
NCT03635632
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 8 |
Top Sponsors
Named interventions
Most-linked intervention names on Relapsed Neuroblastoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Relapsed Neuroblastoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Relapsed Neuroblastoma page
9 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 7 Relapsed Neuroblastoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Stephan Grupp MD PhD sponsors the most Relapsed Neuroblastoma trials on record, review their full trial history before evaluating a specific study. See Stephan Grupp MD PhD's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Relapsed Neuroblastoma condition card totals 9 registered trials; most-linked intervention Irinotecan; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.